GT Biopharma (GTBP) Cash from Operations (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Cash from Operations of 2468000.0 for Q1 2026, down 12.08% year-over-year from 2807095.04 in Q1 2025, and up 38.3% quarter-over-quarter from 4000000.0 in Q4 2025.
GT Biopharma (GTBP) Cash from Operations (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Cash from Operations for 17 consecutive years, with 2468000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 12.08% year-over-year to 2468000.0; the TTM figure through Mar 2026 stood at 13166000.0 (down 20.31% YoY), while the FY2025 annual figure was 12900000.0, changed 0.03% from the prior year.
- Cash from Operations rose to 2468000.0 in Q1 2026 per GTBP's latest filing, from 4000000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1894000.0 in Q2 2023 and bottomed at 5215000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 3078882.35 across 5 years, with a median of 2906000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 52.37% — and 2024, when it slumped 86.69%.
- GT Biopharma's Cash from Operations stood at 4298000.0 in 2022, then surged by 52.37% to 2047000.0 in 2023, then slipped by 20.57% to 2468000.0 in 2024, then slumped by 62.07% to 4000000.0 in 2025, then jumped by 38.3% to 2468000.0 in 2026.
- Business Quant data shows GTBP's Cash from Operations at 2468000.0 in Q1 2026, 4000000.0 in Q4 2025, and 3684000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | -2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.47 Mn |
| Mar 31, 2026 | -2.47 Mn |
| Dec 31, 2025 | -4.00 Mn |
| Dec 31, 2025 | -4.00 Mn |
| Sep 30, 2025 | -3.68 Mn |
| Sep 30, 2025 | -3.68 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Mar 31, 2025 | -2.20 Mn |
| Mar 31, 2025 | -2.20 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | -3.54 Mn |
| Jun 30, 2024 | -3.54 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Dec 31, 2023 | -2.05 Mn |
| Dec 31, 2023 | -2.05 Mn |